A randomized, double-blind, placebo-controlled human clinical trial of 580 subjects to test the efficacy of Ibistrol managing functional dyspepsia.
Functional dyspepsia is a prevalent functional bowel disorder, which includes abdominal distention, fullness feeling, epigastralgia, acid regurgitation, and heartburn. In this study, 410 patients are randomly selected in the treatment group taking two Ibistrol capsules each time, three times a day; 170 patients are put into placebo group. The results after four weeks of treatment are the following:
(1) The comparison of percentage of patients with fullness feeling
after 4 week treatment:
(2) The percentage of patients with abdominal distention and associated symptoms such as nausea, epigastralgia, heartburn, and acid regurgitation after 4-week treatment:
(3) The percentage of patients with vomiting before and after the treatment:
(4) The overall effective rates. The Ibistrol group shows 93 percent overall effective rate.
Human Clinical Studies on Using Ibistrol to Treat Chronic Atrophic Gastritis
A randomized comparison clinical study is conducted of 200 chronic atrophic gastritis (CAG) patients. One hundred and two patients are put into the Ibistrol group and take Ibistrol capsules, while 98 patients in the comparison group take western medicines for one month (two treatment periods). The effective rate of the Ibistrol group is 91.18 percent while that of the comparison group is 83.67 percent. It is also found that the Ibistrol group can treat atypical hyperplasia extremely well, with 100 percent success rate, and it has a better recovery rate than the comparison group.
Graph 5. Effective rates for treating chronic atrophic gastritis
Human Clinical Trial on Using Ibistrol to Treat Chronic Gastritis
A randomized comparison clinical study is conducted of 200 chronic
gastritis patients. There are 130 patients in the Ibistrol group taking
Ibistrol and 71 patients in the comparison group taking western
medicines for one and a half to two months (3-4 treatment period). The
effective rate of the Ibistrol group is 92.2 percent while the
effective rate of the comparison group is 77.5 percent.
Graph 6. The effective rates for treating chronic gastritis
Human Clinical Trial on Using Ibistrol to Treat Seniors’ Habitual Constipation
A randomized comparison clinical study is conducted on 72 senior
patients with habitual constipation. There are 50 patients in the
Ibistrol group taking Ibistrol (three times a day, two capsules/each
time) and 22 patients in the comparison group taking Maziren Pill,
both for one week. The overall effective rate of the Ibistrol group is
92.3 percent while the overall effective rate of comparison group is
85 percent. This study demonstrates that Ibistrol is effective for
treating seniors’ habitual constipation.
Clinical experience on using Ibistrol to treat various digestive disorders
Ibistrol is reported to successfully treat irritable bowel syndromes
such as functional dyspepsia, gastric ulcer, bile-regurgitation
gastritis, and habitual constipation in clinics.
Human Clinical Trial on Using Ibistrol to Treat Hyperlipemia
Human clinical trials also suggest that Ibistrol can effectively lower
blood cholesterol levels, including the levels of TC, TG and LDL – C,
and raise HDL – C level.